<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332822</url>
  </required_header>
  <id_info>
    <org_study_id>NLG-LBC7 POLAR BEAR</org_study_id>
    <nct_id>NCT04332822</nct_id>
  </id_info>
  <brief_title>A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma</brief_title>
  <acronym>POLAR BEAR</acronym>
  <official_title>R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Lymphoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway,
      Finland, Denmark, Italy and Switzerland, in elderly patients with untreated diffuse large
      B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail,
      according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1
      to either the standard treatment for this population, R-miniCHOP, or an experimental regimen,
      R-pola-miniCHP, where vincristine is substituted by an immunoconjugate, polatuzumab vedotin.
      The duration of the screening period is up to 4 weeks. The duration of active treatment is 18
      weeks in both arms, and patients will be followed up to 36 months after end of treatment.
      Start of enrollment is planned in Q1 2020, and the last visit of the last patient included
      (end of trial) is estimated in Q1 2026.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS).</measure>
    <time_frame>2 years.</time_frame>
    <description>The primary end point of this study is PFS. The null hypothesis is that pola-R-mini-CHP is equivalent to R-mini-CHOP. PFS is defined as the interval between registration date and date of documented progression or lack of response, first relapse, or death of any cause. Otherwise, patients will be censored at the last date they were known to be alive. For patients with PD as best response, PFS is defined as 1 day.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>DLBCL</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A - R-mini-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycles 1-6, duration 21 days
Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6
Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - R-pola-mini-CHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles 1-6, duration 21 days
Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-pola-mini-CHP</intervention_name>
    <description>Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6
Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6
Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6
Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg
Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6</description>
    <arm_group_label>Arm B - R-pola-mini-CHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-mini-CHOP</intervention_name>
    <description>Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6
Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6</description>
    <arm_group_label>Arm A - R-mini-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric
             assessment

          -  Histologically confirmed lymphoma belonging to one of the following subtypes:

               1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma

               2. follicular lymphoma grade 3B

               3. T-cell/histiocyte-rich LBCL

               4. primary cutaneous DLBCL, leg type

               5. EBV-positive DLBCL, NOS

               6. primary mediastinal LBCL

               7. high grade B-cell lymphoma with MYC/BCL2 rearrangement

          -  Stage II-IV disease

          -  At least 1 measurable site of disease (&gt;1.5 cm long axis)

          -  No previous treatment for lymphoma

          -  WHO performance status 0 - 3 (Grade 3 if related to DLBCL)

          -  Written informed consent

        Exclusion Criteria:

          -  Severe cardiac disease: NYHA grade 3-4

          -  CNS involvement at diagnosis

          -  Uncontrolled serious infection

          -  Impaired liver (transaminases &gt; 3x normal upper limit or bilirubin &gt; 1.5 x normal
             upper limit, unless due to Gilbert´s syndrome) , renal (GFR&lt;30ml/min) or other organ
             function not caused by lymphoma, which will interfere with the treatment.

          -  Absolute neutrophil count (ANC) &lt;1000 cells/µL or platelets &lt;100,000 cells/µL, unless
             due to lymphoma

          -  Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical
             carcinoma, unless treated with curative intent, and without relapse since 2 years, or
             low grade prostate cancer, not in need of treatment

          -  Psychiatric illness or condition which could interfere with their ability to
             understand the requirements of the study

          -  Known hypersensitivity to rituximab, polatuzumab vedotin, cyclophosphamide,
             vincristine or doxorubicin, or HACA against rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Jerkeman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Skåne University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mats Jerkeman</last_name>
    <phone>0046704973507</phone>
    <email>mats.jerkeman@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department og Hematology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Jakob Madsen</last_name>
      <email>jm@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Jakob Madsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Judit Jörgensen</last_name>
      <email>Judit.Joergensen@aarhus.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Judit Jörgensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic of Hematology L-4241, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Brown</last_name>
      <email>peter.brown@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Peter Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Andriette Dessau-Arp</last_name>
      <email>Andriette.Dessau-Arp@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Andriette Dessau-Arp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Gang</last_name>
      <email>anne.ortved.gang@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Anne Gang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisa Pulczynski</last_name>
      <email>Elisa.Jacobsen.Pulczynski@aarhus.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Elisa Pulczynski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology X, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Stauffer Larsen</last_name>
      <email>Thomas.Stauffer.Larsen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas Stauffer Larsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Zeeland University Hospital Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Bjørn Poulsen</last_name>
      <email>cbpo@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Christian Bjørn Poulsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Clausen</last_name>
      <email>Michael.Roost.Clausen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Michael Clausen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Sirpa Leppä</last_name>
      <email>sirpa.leppa@helsinki.fi</email>
    </contact>
    <investigator>
      <last_name>Sirpa Leppä</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Katja Marin</last_name>
      <email>Katja.marin@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Katja Marin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanne Kuitunen</last_name>
      <email>hanne.kuitunen@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Hanne Kuitunen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marjukka Pollari</last_name>
      <email>marjukka.pollari@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Marjukka Pollari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Sirkku Jyrkkiö</last_name>
      <email>sirkku.jyrkkio@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Sirkku Jyrkkiö</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Spina</last_name>
    </contact>
    <investigator>
      <last_name>Michele Spina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori &quot;Giovanni Paolo II&quot; I.R.C.C.S Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Attilio Guarini</last_name>
    </contact>
    <investigator>
      <last_name>Attilio Guarini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Anna Maria Bolis</last_name>
    </contact>
    <investigator>
      <last_name>Silvia Anna Maria Bolis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Univeristaria Federico II di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandro Severino</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Severino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori &quot;Fondazione Pascale&quot; Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonello Pinto</last_name>
    </contact>
    <investigator>
      <last_name>Antonello Pinto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Luigi Rigacci</last_name>
    </contact>
    <investigator>
      <last_name>Luigi Rigacci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Scientific Institute</name>
      <address>
        <city>Segrate</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Andres Ferreri</last_name>
      <email>Ferreri.AndresJ.M@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andres Ferreri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>logoAzienda Sanitaria Universitaria Integrata di Trieste</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Zaja</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Zaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefano Volpetti</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Volpetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Carlo Visco</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Visco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetshospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Öystein Fluge</last_name>
      <email>oystein.fluge@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Öystein Fluge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalnes Hospital (Østfold)</name>
      <address>
        <city>Grålum</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Dlawer Barzenje</last_name>
      <email>Dlawer.Barzenje@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Dlawer Barzenje</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Adele Mastroianni</last_name>
      <email>maria.adele.mastroianni@ahus.no</email>
    </contact>
    <investigator>
      <last_name>Maria Adele Mastroianni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avd. for Kreftbehandling, Oslo universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Harald Holte</last_name>
      <email>hhe@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Harald Holte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avdeling for Blod- og Kreftsykdommer, Stavanger Universitetssykehus</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Waleed Majeed Mohammed</last_name>
      <email>waleed.majeed.mohammed@sus.no</email>
    </contact>
    <investigator>
      <last_name>Waleed Majeed Mohammed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Maisenhölder</last_name>
      <email>martin.maisenholder@unn.no</email>
    </contact>
    <investigator>
      <last_name>Martin Maisenhölder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kreftklinikken, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Unn Merete Fagerli</last_name>
      <email>unn.merete.fagerli@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Unn Merete Fagerli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset i Vestfold</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Marit Rinde</last_name>
      <email>MRIN@siv.no</email>
    </contact>
    <investigator>
      <last_name>Marit Rinde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken, Södra Älvsborg Sjukhus</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Per-Ola Andersson</last_name>
      <email>per-ola.andersson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Per-Ola Andersson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancercentrum, Onkologkliniken Sörmland, Mälarsjukhuset</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlott Mörth</last_name>
      <email>charlott.morth@regionsormland.se</email>
    </contact>
    <investigator>
      <last_name>Charlott Mörth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology and Coagulation, Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Mariana Villegas Scivetti</last_name>
      <email>mariana.villegas@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mariana Villegas Scivetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Halmstad Country Hospital</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Nevzeta Kuric</last_name>
      <email>nevzeta.kuric@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Nevzeta Kuric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Kalmar County Hospital</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Fredrik Ellin</last_name>
      <email>fredrik.ellin@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Fredrik Ellin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematologiska Kliniken, Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Ingemar Lagerlöf</last_name>
      <email>ingemar.lagerlof@regionostergotland.se</email>
    </contact>
    <investigator>
      <last_name>Ingemar Lagerlöf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Mats Jerkeman</last_name>
      <email>mats.jerkeman@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Mats Jerkeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Hematology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Harrysson</last_name>
      <email>sara.harrysson@sll.se</email>
    </contact>
    <investigator>
      <last_name>Sara Harrysson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Sunderbyn Hospital</name>
      <address>
        <city>Södra Sunderbyn</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Lena Brandefors</last_name>
      <email>lena.brandefors@norrbotten.se</email>
    </contact>
    <investigator>
      <last_name>Lena Brandefors</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uddevalla Sjukhus</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Lina Wide</last_name>
      <email>lina.wide@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Lina Wide</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancercentrum, Norrlands universitetsjukhus</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Sjöström</last_name>
      <email>sara.sjostrom@regionvasterbotten.se</email>
    </contact>
    <investigator>
      <last_name>Sara Sjöström</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Uppsala Academic Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans Hagberg</last_name>
      <email>hans.hagberg@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Hans Hagberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Varberg Hospital</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Carl Simonson</last_name>
      <email>Carl.Simonson@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Carl Simonsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Urban Jerlström</last_name>
      <email>urban.jerlstrom@regionorebrolan.se</email>
    </contact>
    <investigator>
      <last_name>Urban Jerlström</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>Diffuse Large B Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

